- Home
- ATLCP vs REVBW Comparison
ATLCP vs REVBW Comparison
Compare ATLCP & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLCP
- REVBW
- Stock Information
- Founded
- ATLCP N/A
- REVBW N/A
- Country
- ATLCP United States
- REVBW United States
- Employees
- ATLCP 386
- REVBW 9
- Industry
- ATLCP Finance: Consumer Services
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- ATLCP Finance
- REVBW Health Care
- Exchange
- ATLCP Nasdaq
- REVBW Nasdaq
- Market Cap
- ATLCP N/A
- REVBW N/A
- IPO Year
- ATLCP N/A
- REVBW 2020
- Fundamental
- Price
- ATLCP $23.26
- REVBW $0.01
- Analyst Decision
- ATLCP
- REVBW
- Analyst Count
- ATLCP 0
- REVBW 0
- Target Price
- ATLCP N/A
- REVBW N/A
- AVG Volume (30 Days)
- ATLCP N/A
- REVBW N/A
- Earning Date
- ATLCP N/A
- REVBW N/A
- Dividend Yield
- ATLCP N/A
- REVBW N/A
- EPS Growth
- ATLCP N/A
- REVBW N/A
- EPS
- ATLCP N/A
- REVBW N/A
- Revenue
- ATLCP N/A
- REVBW N/A
- Revenue This Year
- ATLCP N/A
- REVBW N/A
- Revenue Next Year
- ATLCP N/A
- REVBW N/A
- P/E Ratio
- ATLCP N/A
- REVBW N/A
- Revenue Growth
- ATLCP N/A
- REVBW N/A
- 52 Week Low
- ATLCP N/A
- REVBW N/A
- 52 Week High
- ATLCP N/A
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- ATLCP 51.66
- REVBW N/A
- Support Level
- ATLCP $22.84
- REVBW N/A
- Resistance Level
- ATLCP $23.30
- REVBW N/A
- Average True Range (ATR)
- ATLCP 0.27
- REVBW 0.00
- MACD
- ATLCP 0.03
- REVBW 0.00
- Stochastic Oscillator
- ATLCP 67.62
- REVBW 0.00
About ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).